José Baselga

As­traZeneca says that treme flubbed an­oth­er com­bo can­cer study, rais­ing fresh doubts about a se­r­i­al los­er

As­traZeneca’s bad­ly dam­aged CT­LA-4 strat­e­gy on the im­muno-on­col­o­gy front has tak­en an­oth­er hit.

The phar­ma gi­ant put out word that the sec­ond leg of its CASPI­AN study failed to demon­strate a sig­nif­i­cant­ly im­proved rate of over­all sur­vival among pa­tients giv­en a triplet of Imfinzi, stan­dard of care and the CT­LA-4 treme­li­mum­ab among front­line small cell lung can­cer pa­tients with ex­ten­sive dis­ease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.